Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥20 years of age~* Histologically confirmed unresectable advanced or recurrent esophageal cancer~* Refractory to or intolerant of standard therapy~* ECOG Performance Status score 0 or 1~* A life expectancy of at least 3 months~Exclusion Criteria:~* Current or past history of severe hypersensitivity to any other antibody products~* Patients with multiple primary cancers~* Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment~* Patients with active, known or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab Arm (Type: EXPERIMENTAL): Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Active Comparator Arm （Docetaxel/Paclitaxel） (Type: ACTIVE_COMPARATOR): Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).